The C-X-C Chemokine Receptor Type 2 pipeline drugs market research report outlays comprehensive information on the C-X-C Chemokine Receptor Type 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the C-X-C Chemokine Receptor Type 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Respiratory, and Metabolic Disorders which include the indications Solid Tumor, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Inflammation, Autoimmune Disorders, Acute Respiratory Distress Syndrome, Chronic Obstructive Pulmonary Disease (COPD), Obesity, and Type 1 Diabetes (Juvenile Diabetes). It also reviews key players involved in C-X-C Chemokine Receptor Type 2 targeted therapeutics development with respective active and dormant or discontinued products.
The C-X-C Chemokine Receptor Type 2 pipeline targets constitutes close to 18 molecules. Out of which, approximately 18 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 2, 4, 2, 8, and 2 respectively.
C-X-C Chemokine Receptor Type 2 overview
CXCR2 or Interleukin 8 receptor, beta is a chemokine receptor. It binds to IL8 with high affinity, and transduces the signal through a G-protein-activated second messenger system. This receptor also binds to chemokine (C-X-C motif) ligand 1 and has shown a major role in serum-dependent melanoma cell growth. This receptor mediates neutrophil migration to sites of inflammation. The angiogenic effects of IL8 in intestinal microvascular endothelial cells are found to be mediated by this receptor.
For a complete picture of C-X-C Chemokine Receptor Type 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
